LifeSci Acquisition Corp. (“LSAC”), Nasdaq: LSAC, LSACU and LSACW, a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors and Vincera Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that they have entered into a definitive agreement for a business combination. The combined company is expected to have approximately $60 million in cash at closing. In addition, it is expected that LSAC will be renamed Vincera Pharma, Inc. and the combined company’s common stock will remain listed on The Nasdaq Capital Market under the new ticker symbol “VINC.”
Read the full article: LifeSci Acquisition Corp. Announces Merger Agreement with Vincera Pharma, Inc. to Create New Publicly Listed Oncology Company //
Source: https://www.globenewswire.com/news-release/2020/09/29/2100519/0/en/LifeSci-Acquisition-Corp-Announces-Merger-Agreement-with-Vincera-Pharma-Inc-to-Create-New-Publicly-Listed-Oncology-Company.html